| scholarly article | Q13442814 |
| P50 | author | Clifford Jack | Q30505709 |
| Jeffrey L Gunter | Q107209317 | ||
| P2093 | author name string | Armando Manduca | |
| Maria M Shiung | |||
| P2860 | cites work | Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease | Q27860795 |
| Accurate, robust, and automated longitudinal and cross-sectional brain change analysis | Q30755158 | ||
| A nonparametric method for automatic correction of intensity nonuniformity in MRI data | Q32061718 | ||
| Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm | Q39512850 | ||
| Automated image registration: I. General methods and intrasubject, intramodality validation | Q41795259 | ||
| The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI. | Q48594940 | ||
| The biomedical imaging resource at Mayo Clinic. | Q53472416 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 16-24 | |
| P577 | publication date | 2003-07-01 | |
| P1433 | published in | Journal of Magnetic Resonance Imaging | Q15761156 |
| P1476 | title | Methodological considerations for measuring rates of brain atrophy | |
| P478 | volume | 18 |
| Q93168346 | A preliminary study of the effects of cannabidiol (CBD) on brain structure in patients with epilepsy |
| Q41104874 | Accelerated Brain Atrophy on Serial Computed Tomography: Potential Marker of the Progression of Alzheimer Disease. |
| Q35686223 | Accelerated vs. unaccelerated serial MRI based TBM-SyN measurements for clinical trials in Alzheimer's disease |
| Q33927219 | Antemortem MRI findings associated with microinfarcts at autopsy |
| Q36251868 | Assessing atrophy measurement techniques in dementia: Results from the MIRIAD atrophy challenge |
| Q30489846 | Atrophy rates accelerate in amnestic mild cognitive impairment |
| Q37326537 | Beta-amyloid burden is not associated with rates of brain atrophy |
| Q46661991 | Blood pressure and progression of cerebral atrophy in patients with vascular disease |
| Q37213765 | Brain and ventricular volumetric changes in frontotemporal lobar degeneration over 1 year |
| Q35327928 | Brain atrophy over time in genetic and sporadic frontotemporal dementia: a study of 198 serial magnetic resonance images |
| Q37366280 | Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. |
| Q55164200 | Brain structure and cognition 3 years after the end of an early menopausal hormone therapy trial. |
| Q48968494 | Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease |
| Q30424864 | Chronic divalproex sodium use and brain atrophy in Alzheimer disease |
| Q37022572 | Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy |
| Q37362582 | Common MRI acquisition non-idealities significantly impact the output of the boundary shift integral method of measuring brain atrophy on serial MRI. |
| Q37313783 | Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD |
| Q33565800 | Comparison of phantom and registration scaling corrections using the ADNI cohort |
| Q35677152 | Comparisons between global and focal brain atrophy rates in normal aging and Alzheimer disease: Boundary Shift Integral versus tracing of the entorhinal cortex and hippocampus |
| Q37217977 | Current and future management of the corticobasal syndrome and corticobasal degeneration |
| Q36205024 | Effects of MRI scan acceleration on brain volume measurement consistency |
| Q30612694 | Effects of aerobic exercise on cognition and hippocampal volume in Alzheimer's disease: study protocol of a randomized controlled trial (The FIT-AD trial) |
| Q48103752 | Effects of gradient non‐linearity correction and intensity non‐uniformity correction in longitudinal studies using structural image evaluation using normalization of atrophy (SIENA) |
| Q37280188 | Effects of hormone therapy on brain structure: A randomized controlled trial |
| Q44682348 | Effects of the use of multiple scanners and of scanner upgrade in longitudinal voxel-based morphometry studies |
| Q41888068 | Evaluation of treatment effects in Alzheimer's and other neurodegenerative diseases by MRI and MRS |
| Q37342678 | Fully automatic segmentation of the brain from T1-weighted MRI using Bridge Burner algorithm |
| Q48616179 | Imaging measures predict progression in progressive supranuclear palsy |
| Q40077283 | Investigation and validation of intersite fMRI studies using the same imaging hardware. |
| Q37550934 | Long-term exercise training for an individual with mixed corticobasal degeneration and progressive supranuclear palsy features: 10-year case report follow-up |
| Q37398634 | Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease |
| Q37402321 | Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. |
| Q37245465 | Mild cognitive impairment due to Alzheimer disease in the community |
| Q48090587 | Modeling trajectories of regional volume loss in progressive supranuclear palsy |
| Q35226739 | Multimodal MRI neuroimaging biomarkers for cognitive normal adults, amnestic mild cognitive impairment, and Alzheimer's disease |
| Q34570703 | Neuropsychological and neuroimaging changes in preclinical Alzheimer's disease |
| Q34715043 | Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies |
| Q36101560 | Rates of brain atrophy and clinical decline over 6 and 12-month intervals in PSP: determining sample size for treatment trials |
| Q36498738 | Rates of brain atrophy over time in autopsy-proven frontotemporal dementia and Alzheimer disease |
| Q37363768 | Rates of cerebral atrophy differ in different degenerative pathologies |
| Q34392779 | Regional brain changes in aging healthy adults: general trends, individual differences and modifiers |
| Q36070362 | Sample size calculations for clinical trials targeting tauopathies: a new potential disease target |
| Q37181302 | Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease |
| Q34500103 | The evolution of primary progressive apraxia of speech |
| Q35119603 | Trajectories of brain and hippocampal atrophy in FTD with mutations in MAPT or GRN. |
| Q46342045 | Validation of the automated method VIENA: an accurate, precise, and robust measure of ventricular enlargement |
| Q35781558 | Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). |
Search more.